6185 logo

CanSino Biologics SZSC:6185 Stock Report

Last Price

HK$33.15

Market Cap

HK$13.0b

7D

18.2%

1Y

42.6%

Updated

07 Dec, 2024

Data

Company Financials +

6185 Stock Overview

Develops, manufactures, and commercializes vaccines in the People’s Republic of China. More details

6185 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for 6185 from our risk checks.

CanSino Biologics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CanSino Biologics
Historical stock prices
Current Share PriceHK$33.15
52 Week HighHK$36.85
52 Week LowHK$14.80
Beta0.46
11 Month Change15.30%
3 Month Change78.42%
1 Year Change42.58%
33 Year Change-78.61%
5 Year Changen/a
Change since IPO-90.92%

Recent News & Updates

Recent updates

Shareholder Returns

6185HK BiotechsHK Market
7D18.2%0.2%3.1%
1Y42.6%-4.8%19.6%

Return vs Industry: 6185 exceeded the Hong Kong Biotechs industry which returned -4.8% over the past year.

Return vs Market: 6185 exceeded the Hong Kong Market which returned 19.6% over the past year.

Price Volatility

Is 6185's price volatile compared to industry and market?
6185 volatility
6185 Average Weekly Movement12.8%
Biotechs Industry Average Movement10.8%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.2%

Stable Share Price: 6185 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6185's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20091,149Xuefeng Yuwww.cansinotech.com

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People’s Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination.

CanSino Biologics Inc. Fundamentals Summary

How do CanSino Biologics's earnings and revenue compare to its market cap?
6185 fundamental statistics
Market capHK$13.01b
Earnings (TTM)-HK$770.60m
Revenue (TTM)HK$801.01m

10.2x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6185 income statement (TTM)
RevenueCN¥748.53m
Cost of RevenueCN¥774.40m
Gross Profit-CN¥25.87m
Other ExpensesCN¥694.25m
Earnings-CN¥720.11m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.91
Gross Margin-3.46%
Net Profit Margin-96.20%
Debt/Equity Ratio41.3%

How did 6185 perform over the long term?

See historical performance and comparison